Real-world survival of patients (pts) with colorectal adenocarcinoma liver metastases (CRLM) treated with transarterial radioembolization (TARE).

医学 对数秩检验 总体生存率 内科学 无进展生存期 肿瘤科 结直肠癌 生存分析 胃肠病学 泌尿科 核医学 癌症
作者
Sharmeen Mahmood,Garo Hagopian,Ben Sadeghi,Jeffrey Kuo,David K. Imagawa,D. Fernando,Nadine Abi-Jaoudeh,Farshid Dayyani
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:41 (4_suppl): 40-40
标识
DOI:10.1200/jco.2023.41.4_suppl.40
摘要

40 Background: While TARE with yttrium-90 (Y90) microspheres can induce tumor responses and improve progression-free survival (PFS) in pts with CRLM, randomized trials have not shown an overall survival (OS) benefit. It is unclear whether this is due to suboptimal pt selection and/or trial design vs. possibly a radiation-induced delayed liver damage which compromises OS. The objective was to describe real world OS with TARE for pts evaluated at an academic center (University of California Irvine) with a dedicated multidisciplinary liver tumor board (MTB). Methods: Retrospective study of consecutive pts with CRLM undergoing TARE between 01/2016-07/2020. We performed descriptive analyses for relevant pt and tumor characteristics, Wilcoxon Signed-Rank Test for comparison of continuous variables, and Kaplan-Meier estimates for survival. Results: N=55 pts were included. Follow-up time was at least 24 mo. Median age was 60 yrs (range 36-84), 61.8% were female, Caucasian/Hispanic/Asian/Other= 54.4%/16.4%16.4%/12.7%, ECOG 0/1/2= 32.7%/58.2%/9.1%, tumor sidedness: left/right/unknown 72.7%/23.6%/3.6%, number or prior lines of systemic treatment 1/2/3+= 38.2%/26.4%/21.8%. MSI-High= 3.6% and RAS/RAF mutations were present/absent/unknown in 34.5%/49.1%/16.4%. Baseline and post-TARE liver function tests are shown in the table. Median time from diagnosis to first TARE was 16.4 mo (1.7-95.6) and 36.4% were treated within the first 12 mo of diagnosis. Median OS from diagnosis and first TARE were 43.2 mo (29.5-68.7) and 16.7 mo (9.9-35.2), respectively. Conclusions: The observed OS of pts with CRLM treated with TARE with a mature follow-up of at least 2 years exceeds 40 mo, despite early integration of TARE in a third of the pts within the first 12 mo of diagnosis. Evaluation of pts with CRLM for TARE at experienced centers with dedicated MTB might lead to improved outcomes. [Table: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
llhh2024发布了新的文献求助20
3秒前
英姑应助科研通管家采纳,获得10
6秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
帅气的逍遥完成签到 ,获得积分10
9秒前
如意竺完成签到,获得积分10
12秒前
wwneen完成签到,获得积分10
14秒前
Kroll发布了新的文献求助10
22秒前
甜美坤完成签到 ,获得积分10
23秒前
25秒前
DL完成签到 ,获得积分10
29秒前
霓娜酱完成签到 ,获得积分10
29秒前
无花果应助tttt采纳,获得10
31秒前
35秒前
45秒前
荔枝完成签到 ,获得积分10
46秒前
海底烤鱼饭完成签到,获得积分10
46秒前
54秒前
冷傲凝琴完成签到,获得积分10
58秒前
云卷云舒完成签到 ,获得积分10
59秒前
忧伤的慕梅完成签到,获得积分10
59秒前
快乐元菱完成签到 ,获得积分10
1分钟前
葱饼完成签到 ,获得积分10
1分钟前
zw完成签到,获得积分10
1分钟前
包容的忆灵完成签到 ,获得积分10
1分钟前
wujiwuhui完成签到 ,获得积分10
1分钟前
香蕉秋寒完成签到 ,获得积分20
1分钟前
orixero应助邓海霞采纳,获得10
1分钟前
Tim完成签到 ,获得积分10
1分钟前
1分钟前
邓海霞完成签到,获得积分10
1分钟前
美好乐松完成签到,获得积分0
2分钟前
JOJO完成签到 ,获得积分10
2分钟前
wuludie应助科研通管家采纳,获得10
2分钟前
wuludie应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
叮叮当当完成签到,获得积分10
2分钟前
janer完成签到 ,获得积分0
2分钟前
2分钟前
yangching完成签到,获得积分10
2分钟前
乌云乌云快走开完成签到,获得积分10
2分钟前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
How Maoism Was Made: Reconstructing China, 1949-1965 800
Barge Mooring (Oilfield Seamanship Series Volume 6) 600
Medical technology industry in China 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3314437
求助须知:如何正确求助?哪些是违规求助? 2946678
关于积分的说明 8531313
捐赠科研通 2622455
什么是DOI,文献DOI怎么找? 1434575
科研通“疑难数据库(出版商)”最低求助积分说明 665329
邀请新用户注册赠送积分活动 650883